David Reeser is one of the millions of Americans whose life has been changed by the ever-evolving, fast-growing epidemic of ...

Charles E. Hamner, Jr., Pd.D., the second president and CEO of the North Carolina Biotechnology Center and a longtime advocate for life sciences in the state, has received the 2024 High Flyer Champion ...

Research Triangle Park-based Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been acquired by a small ophthalmic biopharmaceutical firm with ...

The Triangle is known as a hotbed for innovation, thanks in large part to the partnerships between multiple stakeholders, including universities, investors and ecosystem support organizations. In that ...

Jude Samulski calls genome editing “the next wave of technology to feed the world.” Samulski contributed $3 million to create the Roberts and Mikhail Distinguished Chair in Plant Genome Editing, an ...

Radiopharmaceuticals, once a very niche drug class, are now on the brink of transforming cancer treatment and diagnostics, and North Carolina is at the heart of this change. These radioactive drugs ...

Moderna’s COVID-19 vaccine will soon have a figurative “made in North Carolina” stamp. Thermo Fisher Scientific, a contract manufacturer of pharmaceuticals, will begin making “hundreds of millions of ...

That message is abundantly clear in the newly published analysis, "Evidence & Opportunity 2022: Impact of Life Sciences in NC," which documents why North Carolina continues to garner global admiration ...

SCHOTT Pharma USA, Inc., part of SHOTT Pharma AG, a global specialty glass manufacturer based in Germany, plans to invest $371 million over the next five years to build a new production facility in ...

Summer’s sweltering heat makes autumn seem far away, but at CSL Seqirus in Holly Springs, N.C., it signals shipping time for the company’s portfolio of 2024-2025 seasonal influenza vaccines. On July 9 ...

In the spirit of building a better mousetrap, medical device startup SonoVascular is developing a new technology to more effectively treat patients who have potentially life-threatening blood clots.

Durham-based EydisBio Inc. has received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for EYD-001, a treatment for systemic sclerosis. This rare and debilitating ...